Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial

Reuters

昨天

Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial

Beam Therapeutics Inc. announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, in patients with sickle cell disease $(SCD)$ experiencing severe vaso-occlusive crises. The results, presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, showed that among 31 adult and adolescent SCD patients treated with risto-cel, there was a mean hemoglobin F (HbF) induction of over 60%, hemoglobin S (HbS) reduction to below 40%, and resolution of anemia durable for up to 20 months. The safety profile was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. Additionally, a tiered fixed-dose plerixafor mobilization regimen was found to yield higher CD34+ cell counts and more efficient stem cell collection compared to traditional weight-based dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597866-en) on December 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2589825134"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589825134\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589825134?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589825134","market":"fut","top_or_hot":-1,"title":"Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Beam Therapeutics Inc. announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, in patients with sickle cell disease <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> experiencing severe vaso-occlusive crises. The results, presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, showed that among 31 adult and adolescent SCD patients treated with risto-cel, there was a mean hemoglobin F (HbF) induction of over 60%, hemoglobin S (HbS) reduction to below 40%, and resolution of anemia durable for up to 20 months. The safety profile was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. Additionally, a tiered fixed-dose plerixafor mobilization regimen was found to yield higher CD34+ cell counts and more efficient stem cell collection compared to traditional weight-based dosing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597866-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-06 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Beam Therapeutics Inc. announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, in patients with sickle cell disease <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> experiencing severe vaso-occlusive crises. The results, presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition, showed that among 31 adult and adolescent SCD patients treated with risto-cel, there was a mean hemoglobin F (HbF) induction of over 60%, hemoglobin S (HbS) reduction to below 40%, and resolution of anemia durable for up to 20 months. The safety profile was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. Additionally, a tiered fixed-dose plerixafor mobilization regimen was found to yield higher CD34+ cell counts and more efficient stem cell collection compared to traditional weight-based dosing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597866-en) on December 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL2kX7WP:1","article_id":"2589825134","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589825134","pubTimestamp":1765026020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Beam Therapeutics Inc. announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel , formerly known as BEAM-101, in patients with sickle cell disease  experiencing severe vaso-occlusive crises. The results, presented at the 67th American Society of Hematology  Annual Meeting and Exposition, showed that among 31 adult and adolescent SCD patients treated with risto-cel, there was a mean hemoglobin F  induction of over 60%, hemoglobin S  reduction to below 40%, and resolution of anemia durable for up to 20 months. The safety profile was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. Additionally, a tiered fixed-dose plerixafor mobilization regimen was found to yield higher CD34+ cell counts and more efficient stem cell collection compared to traditional weight-based dosing.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4505":"高瓴资本持仓","BK4535":"淡马锡持仓","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BEAM":"Beam Therapeutics, Inc.","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4611":"AI医疗"},"translate_title":"Beam Therapeutics报告Risto-cel在镰状细胞病试验中的持久疗效和安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BEAM":0.9},"content_text":"Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial\n    \n\n        Beam Therapeutics Inc. announced updated safety and efficacy data from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (risto-cel), formerly known as BEAM-101, in patients with sickle cell disease $(SCD)$ experiencing severe vaso-occlusive crises. The results, presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, showed that among 31 adult and adolescent SCD patients treated with risto-cel, there was a mean hemoglobin F (HbF) induction of over 60%, hemoglobin S (HbS) reduction to below 40%, and resolution of anemia durable for up to 20 months. The safety profile was consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. Additionally, a tiered fixed-dose plerixafor mobilization regimen was found to yield higher CD34+ cell counts and more efficient stem cell collection compared to traditional weight-based dosing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597866-en) on December 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}